Can seliniso cure nkt’s TP53 mutation?

Selinexor (Selinexor) is a small molecule anticancer drug for oral ingestion. It is mainly used to treat multiple types of cancer, including multiple myeloma (Multiple Myeloma) and diffuse largeB-cell lymphoma (Diffuse Large B-cell Lymphoma). In NKT cell-associated tumors, TP53 gene mutations are frequently associated with disease progression and poor prognosis. The TP53 gene encodes p53 protein, which is an important tumor suppressor protein involved in cell cycle regulation, DNA repair and induction of apoptosis.

Research shows that Tumors with TP53 mutations are usually highly resistant to traditional chemotherapy drugs, and selinesol increases the sensitivity of cancer cells to anti-cancer drugs by inhibiting the nuclear export mechanism in tumor cells. Therefore, selinesol may have some therapeutic potential for tumors harboring TP53 mutations, especially when combined with other treatments.

NKT cells (natural killer T cells) are a special type of lymphocytes with important immune regulatory functions. The TP53 gene is a gene encoding the tumor protein p53. p53 has important functions in cells such as regulating cell cycle, DNA repair and apoptosis. TP53 mutation is one of the common gene mutations in many malignant tumors. Research on the use of selinesol in the treatment of TP53 mutations in NKT cells is currently limited, and there are no large-scale clinical trials or data dedicated to this specific subpopulation to refer to. Therefore, it is not possible to answer with certainty whether selinexole can treat TP53 mutations in NKT cells.

In addition, the side effects of selinesol also need to be paid attention to. Common adverse reactions include fatigue, nausea, vomiting, bone marrow suppression, etc. Therefore, before applying selinesol treatment, doctors need to conduct a comprehensive evaluation based on the patient's overall health status, previous treatment history, and tumor characteristics.